7/16/2019  5:15:14 PM Chg. +0.29 Volume Bid7:59:50 PM Ask7:59:50 PM Market Capitalization Dividend Y. P/E Ratio
81.80EUR +0.36% 0
Turnover: 0.00
-Bid Size: - -Ask Size: - 57.49 bill.EUR - -

Business description

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
 

Management board & Supervisory board

CEO
Mark J. Alles
Management board
David V. Elkins, Aijaz Tobaccowalla, Dr. Alise Reicin, Jay T. Backstrom, Jennifer Dudinak, Joanne Beck, Jonathan Biller, Joseph Hand, Nadim Ahmed, Peter N. Kellogg, Richard Bagger, Robert Hershberg, Rupert Vessey, Terrie Curran, Toni-Ann Citera
Supervisory board
Mark Alles, Carrie S. Cox, Dr. Ernest Mario, Dr. Richard W. Barker, Hans Bishop, James Loughlin, John H. Weiland, Julia A. Haller, Michael A. Friedman, Michael D. Casey, Michael W. Bonney, Patricia Hemingway Hall
 

Company data

Name: Celgene Corp.
Address: 86 Morris Avenue,Summit, NJ 07901, USA
Phone: +1-908-673-9000
Fax: -
E-mail: -
Internet: www.celgene.com
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 84.90%
IPO date: -

Investor relations

Name: Patrick E. Flanigan III
IR phone: +1-908-673-9628
IR Fax: -
IR e-mail: ir@celgene.com

Main Shareholders

Freefloat
 
84.90%
BlackRock, Inc.
 
7.60%
The Vanguard Group, Inc.
 
7.50%